From human embryonic and induced pluripotent stem cells to skeletal satellite cells for muscle dystrophies therapy

Progress of cell therapy for muscular dystrophies is slow. Although there are clinical trials of myoblast delivery, the result is not satisfactory. However, human stem cell, especially induced pluripotent stem cells (iPSCs) could overcome the problem by successful differentiation. Generally speaking, there are two strategies for that goal, one is by plasmid and the other is by differentiation factors in vitro. This review covers recent advances in the differentiation field of human embryonic stem cells (ESCs) and iPSCs, showing different differentiation methods as a potential therapy way.